-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Beam Therapeutics, Raises Price Target to $30

Benzinga·11/04/2026 14:28:03
Diffusion vocale
Wedbush analyst David Nierengarten maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform and raises the price target from $28 to $30.